Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept (Sebivo/Tyzeka)

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by Novartis
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01379508
First received: June 21, 2011
Last updated: June 18, 2014
Last verified: June 2014

June 21, 2011
June 18, 2014
March 2011
January 2016   (final data collection date for primary outcome measure)
the aggregated rate of HBV DNA < 300 copies/mL (51 IU/mL) at week 52 of Telbivudine (ARM 1) is non-inferior to Tenofovir (ARM 2). [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
The primary objective of the study is to compare the efficacy of Roadmap-Concept-based telbivudine treatment versus Roadmap-Concept-based tenofovir treatment in HBeAg-negative CHB patients. The rate of HBV DNA < 300 copies/mL (51 IU/mL) at week 52 will be used for the comparison of the efficacy. The hypothesis is that the aggregated rate of HBV DNA < 300 copies/mL (51 IU/mL) at week 52 of Telbivudine (ARM 1) is non-inferior to Tenofovir (ARM 2).
The primary objective of the study is to compare the efficacy of Roadmap-Concept-based telbivudine treatment versus Roadmap-Concept-based tenofovir treatment in HBeAg-negative CHB patients [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]
The primary objective of the study is to compare the efficacy of Roadmap-Concept-based telbivudine treatment versus Roadmap-Concept-based tenofovir treatment in HBeAg-negative CHB patients. The rate of HBV DNA < 300 copies/mL (51 IU/mL) at week 52 will be used for the comparison of the efficacy. The hypothesis is that the aggregated rate of HBV DNA < 300 copies/mL (51 IU/mL) at week 52 of Telbivudine (ARM 1) is non-inferior to Tenofovir (ARM 2).
Complete list of historical versions of study NCT01379508 on ClinicalTrials.gov Archive Site
  • antiviral efficacy by the rate of patients achieving HBV DNA < 300 copies/ml at Week104, and at Week156 [ Time Frame: 104 weeks; 156 weeks ] [ Designated as safety issue: No ]
    To assess the antiviral efficacy, as evaluated by rate of patients achieving HBV DNA <300 copies/mL (51 IU/mL) at Week104, at Week156. In patients who achieve HBV DNA <300copies at Week 104, rate of patients with maintained HBV DNA <300 copies at Week 156
  • antiviral efficacy by serum HBV DNA reduction and time to achieve HBV DNA <300 copies/ml at Week104, and at Week156 [ Time Frame: over the course of the study ] [ Designated as safety issue: No ]
    To assess the antiviral efficacy, as evaluated by serum HBV DNA reduction from baseline, and time to achieve HBV DNA < 300 copies/mL (51 IU/mL). In patients who achive HBV DNA < 169 copies/ml at Week104, teh rate of patients with maintained HBV DNA <169 copies at Week156.
  • rate of HBsAg loss [ Time Frame: over the course of the study ] [ Designated as safety issue: No ]
    To assess the rate of HBsAg loss and HBsAg seroconversion (defined as loss of HBsAg and development of HBsAb) over the course of the study
  • biochemical efficacy [ Time Frame: Week 52; Week 104; Week 156 in patients with elevated ALT at baseline. ] [ Designated as safety issue: No ]
    To assess the biochemical efficacy as evaluated by rate of patients with ALT normalization
  • safety endpoint [ Time Frame: at Week 52, Week 104 and Week 156 ] [ Designated as safety issue: Yes ]
    To assess the safety endpoints as evaluated by incidence of death, AE, SAE, AESI and graded laboratory abnormalities
  • eGFR change in telbivudine arm vs tenofovir Arm over the course of the study [ Time Frame: 52 weeks, 104 weeks, 156 weeks ] [ Designated as safety issue: No ]
    eGFR changes from baseline to Week52, Week104 and Week156 for the overall population and sub-populations of patients with renal function impairment at baseline (eGFR 60-90 ml/min/1.73m2 or 60-80 ml/min/1.73m2). Percentage of patients with abnormal baseline eGFR shifting to normal eGFR at Week52, Week104 and Week156
  • To assess the antiviral efficacy, as evaluated by rate of patients achieving HBV DNA <300 copies/mL (51 IU/mL) [ Time Frame: 104 weeks ] [ Designated as safety issue: No ]
  • To assess the antiviral efficacy, as evaluated by serum HBV DNA reduction from baseline, and time to achieve HBV DNA < 300 copies/mL (51 IU/mL). [ Time Frame: over the course of the study ] [ Designated as safety issue: No ]
  • To assess the rate of HBsAg loss and HBsAg seroconversion (defined as loss of HBsAg and development of HBsAb) over the course of the study [ Time Frame: over the course of the study ] [ Designated as safety issue: No ]
  • To assess the biochemical efficacy as evaluated by rate of patients with ALT normalization [ Time Frame: Week 52 and 104 in patients with elevated ALT at baseline. ] [ Designated as safety issue: No ]
  • To assess the safety endpoints as evaluated by incidence of death, AE, SAE, AESI and graded laboratory abnormalities [ Time Frame: at Weeks 52 and 104 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept
OPTIMA: A Randomized, Open-label, 156-week Treatment Study to Evaluate the Efficacy and Safety of Telbivudine or Tenofovir Treatment in HBeAg-negative Chronic Hepatitis B Patients Based on the Roadmap Concept

The purpose of this study is to evaluate the efficacy and safety following the Roadmap Concept strategy with an initial monotherapy using either telbivudine or tenofovir in HBeAg negative CHB patients. The data from the study should allow for the validation of the Roadmap concept in a prospective manner, for both telbivudine and tenofovir treated HBeAg negative CHB patients. As part of a post-approval commitment to the European Health Authorities, the data will also be used to provide an optimized clinical treatment strategy for better clinical use of telbivudine in European HBeAg negative patients. Furthermore, the data from the study will contribute to a better scientific understanding, disease management and treatment of HBeAg negative CHB patients.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Chronic Hepatitis B
  • Drug: Telbivudine 600mg
    Other Name: LDT600
  • Drug: Tenofovir disoproxil fumarate 300mg
  • Experimental: Arm 1
    Intervention: Drug: Telbivudine 600mg
  • Active Comparator: Arm 2
    Intervention: Drug: Tenofovir disoproxil fumarate 300mg
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
240
January 2016
January 2016   (final data collection date for primary outcome measure)

Inclusion Criteria:

Male or female, at least 18 years of age

Documented compensated HBeAg negative CHB defined by all of the following:

  • Detectable serum HBsAg at screening visit and at least 6 months prior;
  • HBeAg negative at the screening visit with positive HBeAb;
  • Serum HBV DNA > 2000 IU/mL Serum ALT level > 1×ULN and <10×ULN at screening visit; patient with normal ALT ≤1xULN at screening are eligible, with moderate liver inflammation or fibrosis, complensated liver sirrhosis, ALT level >1xULN wtihin last 6 months

Exclusion Criteria:

  • Co-infected with HCV, HDV or HIV.
  • Received treatment of nucleoside or nucleotide drugs at any time
  • Received IFN or other immunomodulatory treatment within six months before Screening
  • Pregnant or nursing (lactating) women
  • Clinical signs/symptoms of hepatic decompensation
  • History of myopathy, myositis or persistent muscle weakness
  • history of clinical and laboratory evidence of chronic renal insufficency
Both
18 Years and older
No
Contact: Novartis Pharmaceuticals +41613241111
Contact: Novartis Pharmaceuticals
Russian Federation,   Austria,   Bulgaria,   Germany,   Greece,   Italy,   Turkey,   Spain
 
NCT01379508
CLDT600A2409, 2007-000180-13
No
Novartis ( Novartis Pharmaceuticals )
Novartis Pharmaceuticals
Not Provided
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Novartis
June 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP